Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jan 20, 2026
5 Surprising Reasons the VB ETF Could Rally 25% in 2026 — AI Models Highlight Overlooked Opportunities

5 Surprising Reasons the VB ETF Could Rally 25% in 2026 — AI Models Highlight Overlooked Opportunities

Introduction

The Vanguard Small-Cap Value ETF (VB) is quietly standing out in what has been a turbulent start to 2026. While many small-cap segments have struggled, VB has shown notable resilience, including a 3.2% jump on January 14, driven by renewed buying interest in undervalued industrial and financial stocks. This divergence from broader small-cap weakness suggests early signs of mean reversion, particularly as incoming economic data points toward eventual interest-rate relief.

For traders and investors watching sector rotation closely, VB’s behavior may be signaling that small-cap value is regaining favor just as macro headwinds begin to ease.

Key Takeaways

  • Value momentum is strengthening, with VB’s RSI pushing above 55 for the first time in several weeks.

  • AI-based corridor models are identifying low-volatility zones that favor swing-trade entries.

  • Multi-agent trading strategies indicate potential upside of 15–20% if capital rotation into small-caps accelerates.

  • VB’s risk-adjusted Sharpe ratio above 1.2 is outperforming many small-cap growth peers year to date.

  • Inverse ETF pairings provide effective hedges against sudden macro-driven drawdowns.

Global Market Backdrop

Global equity markets continue to digest policy shifts following President Trump’s January 2025 inauguration, including renewed tariff measures that have weighed on small-cap supply chains. At the same time, easing inflation—now near 2.1%—and expectations for a Federal Reserve pause are creating a more favorable environment for value-oriented assets.

International developments are also influencing sentiment. Stronger-than-expected economic data from Germany and fresh stimulus signals out of China are supporting cyclical sectors, many of which are heavily represented in VB’s portfolio. Meanwhile, crude oil’s decline below $70 per barrel is helping smaller energy producers, and Bitcoin’s renewed rally appears to be redirecting speculative capital back toward traditional equity value plays.

Tickeron AI Performance and Innovation

Tickeron’s AI Trading Robots are designed to capitalize on precisely these types of market transitions. For VB, specialized 60-minute trading agents generate high-frequency signals based on real-time momentum and price-action data.

These tools include:

  • Corridor models for navigating range-bound markets

  • Single-agent systems optimized for short-term momentum trades

  • Multi-agent frameworks coordinating signals across timeframes for enhanced risk control

  • 2-ETF and 3-ETF strategies pairing VB with growth or fixed-income assets to improve diversification

Together, these AI-driven approaches aim to capture consistent alpha while adapting dynamically to shifting volatility.

AI-Based Trading Outlook

Tickeron’s AI models currently favor VB during periods of moderate trend strength, particularly when MACD crossovers align with volatility below 25%. The system actively scans for breakout patterns within VB’s core holdings, such as regional banks and industrials, emphasizing momentum-driven bursts over choppy price action.

Swing-trade setups remain especially attractive, with multi-agent strategies deploying tight 2% stop-loss thresholds while targeting 4:1 reward-to-risk ratios—a profile well-suited to today’s small-cap value discount.

Conclusion and AI Forecast

Looking ahead to 2026, VB’s outlook remains constructively bullish. AI-driven projections suggest potential gains of 18–25% if Federal Reserve rate cuts materialize and pro-business domestic policies support smaller companies. Earnings growth among industrial holdings—estimated at around 12% EPS expansion—adds further support to the value-rotation thesis.

That said, downside risks persist. A renewed recession scare or escalating trade tensions could reintroduce volatility and cap upside. For traders seeking disciplined exposure, deploying Tickeron’s AI Trading Robots may provide a systematic way to capture opportunities while managing risk in what appears to be a high-conviction small-cap value setup for 2026.

Disclaimers and Limitations

Related Ticker: VB

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


VB sees its Stochastic Oscillator ascends from oversold territory

On October 02, 2026, the Stochastic Oscillator for VB moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 54 instances where the indicator left the oversold zone. In 50 of the 54 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where VB's RSI Indicator exited the oversold zone, 22 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.

The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on VB as a result. In 81 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.

The Moving Average Convergence Divergence (MACD) for VB just turned positive on October 02, 2026. Looking at past instances where VB's MACD turned positive, the stock continued to rise in 49 of 54 cases over the following month. The odds of a continued upward trend are 90%.

Following a +1.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where VB advanced for three days, in 277 of 328 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

VB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

VB moved below its 50-day moving average on August 31, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for VB crossed bearishly below the 50-day moving average on September 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

The Aroon Indicator for VB entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Twilio (NYSE:TWLO), Illumina (NASDAQ:ILMN), Okta (NASDAQ:OKTA), EQT Corp (NYSE:EQT), Centene Corp (NYSE:CNC), Incyte Corp (NASDAQ:INCY), Guardant Health (NASDAQ:GH), Roku (NASDAQ:ROKU), Dow (NYSE:DOW).

Industry description

The investment seeks to track the performance of the CRSP U.S. Small Cap Index that measures the investment return of small-capitalization stocks. The fund advisor employs an indexing investment approach designed to track the performance of the CRSP U.S. Small Cap Index, a broadly diversified index of stocks of small U.S. companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.

Market Cap

The average market capitalization across the Vanguard Morningstar Small-Cap ETF (VB) ETF is 6.83B. The market cap for tickers in the group ranges from 189.9M to 78.76B. MRNA holds the highest valuation in this group at 78.76B. The lowest valued company is EVGO at 189.9M.

High and low price notable news

The average weekly price growth across all stocks in the Vanguard Morningstar Small-Cap ETF (VB) ETF was 2%. For the same ETF, the average monthly price growth was -3%, and the average quarterly price growth was 7%. RXO experienced the highest price growth at 42%, while LQDA experienced the biggest fall at -62%.

Volume

The average weekly volume growth across all stocks in the Vanguard Morningstar Small-Cap ETF (VB) ETF was 3%. For the same stocks of the ETF, the average monthly volume growth was 21% and the average quarterly volume growth was -24%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 54
Price Growth Rating: 55
SMR Rating: 64
Profit Risk Rating: 75
Seasonality Score: 32 (-100 ... +100)
View a ticker or compare two or three
VB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category SmallBlend

Category
Small Blend
Address
Vanguard Index FundsPO Box 2600Valley Forge
Phone
800-523-1036
Web
www.vanguard.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
Patterson-UTI Energy, Inc. (PTEN) stands out as a leading provider of drilling and completion services to oil and natural gas exploration and production companies, primarily in the United States and select international markets. The company operates through three main segments: Drilling Services, which includes contract drilling rigs and directional drilling; Completion Services, encompassing hydraulic fracturing, wireline, and pumping; and Drilling Products, offering specialized drill bits globally, including in the Middle East.
As a provider of onshore drilling and completion services, Patterson-UTI Energy (PTEN) is gearing up for a key Q1 2026 earnings report against the backdrop of fluctuating oil prices and steady U.S. rig demand. The company's integrated approach across Drilling Services, Completion Services, and Drilling Products gives it a solid footing in North American shale plays. In my view, recent quarters like Q4 2025, where revenue exceeded estimates despite a net loss, highlight its resilience. This upcoming report will offer insights into activity levels, margin trends, and capital discipline amid supply growth and geopolitical tensions. With strong free cash flow and recent dividend increases, PTEN's focus on shareholders stands out, making this a critical gauge for the 2026 outlook in the cyclical oilfield services sector.
When geopolitical turmoil sends markets into chaos, most retail traders freeze — but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 — trading six of the most volatile and opportunity-rich energy tickers on the market.
The global energy sector is on fire — literally and figuratively. With crude oil prices swinging 20–30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas – E&P) AI Trading Agent — a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.